Comparative Pharmacology
Head-to-head clinical analysis: CLOBAZAM versus FLURAZEPAM HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOBAZAM versus FLURAZEPAM HYDROCHLORIDE.
CLOBAZAM vs FLURAZEPAM HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
None Documented
None Documented
Clobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clobazam."
Clinical Note
moderateClobazam + Erythromycin
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Erythromycin can be decreased when combined with Clobazam."